Katarina Uttervall

Publications
CV
Public outreach and news

Articles

Article: CANCER MEDICINE. 2024;13(8):e7048
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden
Uttervall K; Taetting L; Lemonakis K; Majd M; Crafoord J; Olsson M; Mellqvist U-H; Hansson M; Nahi H
Article: CANCERS. 2024;16(5):1024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Partanen A; Waage A; Peceliunas V; Schjesvold F; Anttila P; Saeily M; Uttervall K; Putkonen M; Carlson K; Haukas E; Sankelo M; Szatkowski D; Hansson M; Marttila A; Svensson R; Axelsson P; Lauri B; Mikkola M; Karlsson C; Abelsson J; Ahlstrand E; Sikioe A; Klimkowska M; Matuzeviciene R; Fenstad MH; Ilveskero S; Pelliniemi T-T; Nahi H; Silvennoinen R
Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Afram G; Susek KH; Uttervall K; Wersall JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(6):588-596
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Bruchfeld JB; Wallblom A; Alici E; Gahrton G; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Uttervall K; Bruchfeld JB; Gran C; Walinder G; Mansson R; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;99(3):216-222
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
Nahi H; Genell A; Walinder G; Uttervall K; Juliusson G; Karin F; Hansson M; Svensson R; Linder O; Carlson K; Bjorkstrand B; Kristinsson SY; Mellqvist UH; Blimark C; Turesson I
Article: PLOS ONE. 2015;10(9):e0138248
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Kviele HH; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Nasman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: PLOS ONE. 2014;9(7):e101819
The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: MEDICAL ONCOLOGY. 2012;29(3):2191-2199
Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery
Ungerstedt JS; Watz E; Uttervall K; Johansson B-M; Wahlin BE; Nasman P; Ljungman P; Gruber A; Nygell UA; Nahi H

All other publications

Meeting abstract: BLOOD. 2023;142:1960
A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk
Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Meeting abstract: BLOOD. 2022;140:12605-12606
Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
Uttervall K; Nahi H; Kashif M; Lemonakis K; Rosengren S; Brolin J; Lund J; Hansson M
Meeting abstract: BLOOD. 2021;138:897
DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Callander NS; Ribrag V; Richardson PG; Nooka AK; Song K; Uttervall K; Minnema MC; Weisel K; Quach H; Min C-K; Ballas MS; Li XF; Ratia N; Kaisermann M; Holkova B; Tudel S
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Meeting abstract: BLOOD. 2012;120(21):5033
Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients
Uttervall K; Andreasson J; Liwing J; Nasman P; Aschan J; Nahi H
Meeting abstract: BLOOD. 2012;120(21):2970
Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population
Nahi H; Liwing J; Aldrin A; Andreasson J; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Johansson P; Kviele H; Lauri B; Mellqvist U-H; Nasman P; Swedin A; Svensson M; Uttervall K; Aschan J

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2022-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2015
University Medical Degree, Karolinska Institutet, 2009

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI